All posts by medical

Immunology

VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May – GlobeNewswire

TEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the company will present new data on its novel Monocyte Targeting Technology and lead candidate VB-601 at IMMUNOLOGY2022TM being held in Portland, OR on May 6 10, 2022. In addition, Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will discuss the VB-601 program at the LifeSci Immunology & Inflammation Symposium being held virtually on May 11, 2022. Prof. Harats will also provide a keynote presentation at the Biomed Israel 2022 Conference on May 12, 2022, and a corporate overview at the H.C. Wainwright Global Investment Conference taking place May 23 May 26, 2022.

IMMUNOLGY2022TMDate: Sunday, May 8th, 2022 Time: 2:30 p.m. PDTSession Title: They Come and They Go: A Leukocyte Migration ExtravaganzaPoster Title: MOSPD2 regulates the activation state of L2 integrinto control monocyte migration

LifeSci Immunology & Inflammation SymposiumDate: Wednesday, May 11th, 2022 Time: 1:00 p.m. to 1:30 p.m. EDTFormat: Overview of VBLs VB-601 ProgramRegistration details for the event can be found here

Biomed Israel 2022 ConferenceDate: Thursday, May 12th, 2022 Track: Transformative Precision Cancer Diagnostics and TherapiesTime: 9:30 a.m. to 2:00 p.m. IDTFormat: Corporate Overview Registration details for the event can be found here

H.C. Wainwright Global Investment ConferenceDate: Monday, May 23rd - Thursday, May 26th, 2022Format: Corporate Overview

Links to VBLs IMMUNOLGY2022TM poster and to the webcast of the LifeSci Symposium will be available on the Events and Presentations page of the Investors section on the Companys website at http://www.vblrx.com.

About VBL TherapeuticsVascular Biogenics Ltd., operating asVBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications. VBLs novel VTS gene-based platform and antibody-based monocyte targeting technology enable the creation of a pipeline of programs that are designed to harness the bodys innate biological processes to provide unique solutions for significant unmet medical needs. VBLs lead oncology product candidate, ofra-vec (ofranergene obadenovec; `VB-111`), is an investigational targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors. Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer. To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.

CONTACT:Daniel FerryLifeSci Advisors+1 (617) 430-7576daniel@lifesciadvisors.com

Read the original post:
VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May - GlobeNewswire

Immunology

Ventus Therapeutics Appoints Stuart Green, M.D., as Chief Medical Officer – Business Wire

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today the appointment of Stuart Green, MD, as Chief Medical Officer.

Dr. Green has broad experience and a proven track record in clinical development across a wide range of programs, including his most recent leadership role overseeing late-stage clinical trials at Merck Research Laboratories.

We are excited to welcome Stuart to the Ventus team at this pivotal time in our evolution toward a clinical-stage company. His caliber as a leader and extensive background in clinical development will be invaluable as we continue to advance our pipeline, said Marcelo Bigal, M.D., Ph.D., president and CEO of Ventus. In addition, his expertise in inflammation and immunology is a tremendous asset, as these therapeutic areas include some of the key diseases targeted by our innovative small molecule medicines.

I am gratified by the opportunity to join Ventus as CMO, and I look forward to leading the clinical development of the companys promising small molecule therapeutics for challenging drug targets in diseases with unmet medical needs, said Dr. Green. The team has built an impressive suite of technologies in the ReSOLVE drug discovery platform and has rapidly generated a pipeline of novel small molecule medicines that offer the potential for compelling new treatments for patients.

Dr. Green brings more than twenty years of experience in clinical development to Ventus. Most recently, he was head of late-stage clinical development in respiratory and immunology at Merck Research Laboratories. During his time at Merck, Dr. Green oversaw pivotal Phase 2/3 clinical development across a wide range of programs, including original drug application approvals for ILUMYA, GRASTEK, and RAGWITEK, as well as supplemental approvals for EMEND/EMEND FOR INJECTION, SIMPONI, and ARCOXIA. In addition, he led multiple development programs in asthma, COPD, rheumatoid arthritis, overactive bladder, and chronic cough. While at Merck, he also played a leadership role in business development and licensing activities, including successful acquisitions of Afferent Pharmaceuticals, OncoImmune, and Pandion Therapeutics. Dr. Green received a B.S. in Chemistry from Duke University and an M.D. from the University of Tennessee Center for the Health Sciences. He completed an internship and residency in Internal Medicine at Duke University Medical Center, and a fellowship in Pulmonary and Critical Care Medicine at Duke and the University of Cincinnati.

About Ventus TherapeuticsVentus Therapeutics is a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of disease indications, with an initial focus on immunology, inflammation and neurology. We have developed a proprietary drug discovery platform, called ReSOLVE, which is built upon our structural biology and protein science expertise and our proprietary computational chemistry capabilities, to address the current limitations of small molecule drug discovery. We are leveraging our ReSOLVE platform to discover and characterize previously unknown or poorly understood pockets on the surface of proteins and identify small molecules that can bind to those pockets with optimal affinity. We are focused on high-value targets that have been extensively implicated in human diseases that were previously considered undruggable or where we believe there is a significant opportunity to improve upon existing therapies. Our lead programs target key innate immune modulators, including NLRP3 and cGAS. For more information, please visit http://www.ventustx.com and engage with us on Twitter @Ventus_Tx or on LinkedIn.

Forward-Looking StatementsThis press release contains forward-looking statements about future expectations, plans and prospects, including, but not limited to, statements related to the anticipated benefits of executive leadership team additions, our business strategy, current programs, and timing of planned preclinical and clinical activities and future results of operations and financial position. These forward-looking statements are based on our current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the timing, progress and results of preclinical and clinical studies involving our development programs; the results of our earlier studies not being predictive of future results; our ability to enhance the ReSOLVE platform; our ability to continue to obtain funding for our operations and implement our business strategy; the impact of the COVID-19 pandemic on our business and our efforts to address its impact on our business; anticipated developments related to our competitors and our industry; the performance of third-party service providers, including suppliers and manufacturers; and our ability to obtain, maintain and protect our intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and we undertake no duty or obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Visit link:
Ventus Therapeutics Appoints Stuart Green, M.D., as Chief Medical Officer - Business Wire

Immunology

IDNA: A Long Term Prospect, Slowly Overcoming The Bearish Rally – Seeking Alpha

DanielPrudek/iStock via Getty Images

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) is a healthcare exchange traded fund (ETF) launched by BlackRock, Inc. in June 2019, i.e., less than three years back. This ETF is managed by BlackRock Fund Advisors and has an Asset Under Management (AUM) of $209 million. It invests in public equity shares in all the major stock markets worldwide, with 60 percent investments in the US stock market. This ETF has around 11 percent investments in the Japanese stock market and 24 percent investments in European equity markets.

iShares Genomics Immunology and Healthcare ETF primarily invests in biotechnology and pharmaceutical stocks. It has also invested around 3 percent in a dividend fund, namely Eaton Vance Tax-Advantaged Dividend Income Fund (EVT). IDNA benchmarks the performance of its portfolio against the NYSE FactSet Global Genomics and Immuno Biopharma Index. This index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

iShares Genomics Immunology and Healthcare ETF is a relatively new ETF, launched less than three years ago, and is operating with an expense ratio of 0.47 percent. This ETF is not meant for income-seeking investors, as it intends to pay semi-annual dividends, but with a very low yield. The average year-end yield of the past three years has been less than 0.6 percent. Thus, the investment decision will solely depend upon the expected future performance of the fund over the long run.

iShares Genomics Immunology and Healthcare ETF has performed poorly over the past 12 months. IDNA has recorded a negative growth of around 9 percent, 40 percent, and 38 percent over the past three months, six months, and 12 months, respectively. We all know that the biotechnology sector had an extremely poor last six months in 2021. Still, for a growth-seeking ETF to generate a negative return of that high percentage may make the investors skeptical.

An analysis of IDNA's top 30 common equity holdings (holding 90 percent of the entire portfolio) reveals that most of its investments are in biotechnology stocks. Out of these 30 equities, 24 biotechnology stocks (22 are listed in the US stock market) are holding more than 60 percent of its total portfolio.

Only five stocks are from the pharmaceutical sector, holding around 26 percent of its total portfolio. Incidentally, all these five stocks are listed outside the United States. One of IDNA's top holdings (3.85 percent of total portfolio), Maravai LifeSciences Holdings, Inc. (MRVI), belongs to the life sciences tools & services industry.

Barring Regeneron Pharmaceuticals, Inc. (REGN), all the biotechnology and life science companies listed in the New York Stock Exchange (NYSE) have recorded negative price growth over the past 12 months. This explains the massive loss of IDNA's price over the past one year. Another company, Exelixis, Inc. (EXEL) recorded positive price growth over the past six months.

Another three stocks - Maravai LifeSciences Holdings, Inc., Iovance Biotherapeutics, Inc. (IOVA), and Genmab A/S (GMAB) - recorded double-digit positive growth in the past three months. Thus, this ETF seems to be slowly recovering from the steep downfall in the second half of 2021. Still, it has a long way to go, as 20 such companies are yet to recover themselves.

iShares Genomics Immunology and Healthcare ETF, however, has posted a price growth of 22 percent since its inception in June 2019. This suggests that this ETF has performed very well in the first two years of its operation, and the stocks included in this ETF are quite volatile. There are other genomic revolution funds like Invesco Dynamic Biotechnology & Genome Portfolio ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM) and ARK Genomic Revolution ETF (ARKG), which also performed poorly last year. The similar trend is visible in most of the funds - huge price loss in the past 12 months, but positive price gain since June 2019 (the time when IDNA was launched).

Despite the market price falling by 61.1 percent in the past one year, ARKG registered a growth of 3.3 percent over the past three years. PBE's price also fell by 25.3 percent in the past one year but grew by 7.8 percent over the past three years. Only GNOM failed miserably and recorded a negative growth of 44.5 percent and 13.9 percent growth over the past one year and three years, respectively. During the same period, S&P 500 OTC:GREW by 4 percent and 53 percent, respectively.

Weighted average Price to Equity ratio of the component stocks of iShares Genomics Immunology and Healthcare ETF comes to around 14.29, compared to the index's Price to Equity ratio of 16.67. IDNA's Price to Book ratio is 2.23, compared to the index's Price to Book ratio of 3.98. This suggests that the ETF is slightly undervalued. This assumption gets further validation as the price/sales of 1.27, and price/cash flow of 9.7, is relatively lower than the index (Price/Sales of 1.64 and Price/Cash Flow of 13.35).

However, the iShares Genomics Immunology and Healthcare ETF is currently trading at only 3 percent premium over its 52-week low, and there is scope for a further downward rally of this fund, as indicated by the simple moving averages (SMA). The long-term moving averages of this fund are placed significantly higher than the short-term moving averages. As of 28th April 2022, the 200-day SMA (43.67), 100-day SMA (36.73), 50-day SMA (33.54) and 10-day SMA (31.82) are indicative of a bearish rally for this ETF.

Thus, there lies every possibility of stiff downward movement with every downward trend in the market. Moreover, being a theme-based biotechnology index fund, IDNA cannot overcome its inherent volatility and market risk, which may arise due to changes in investors' sentiment or any negative news about its constituent stocks or the sector as a whole. The possibility of most of the stocks in its portfolio generating positive returns will take time, maybe another six to nine months. However, a course correction for IDNA is very much possible, too, if the biotechnology sector gets some positive boost or gets into any bull run.

In my opinion, iShares Genomics Immunology and Healthcare ETF can only be considered as a medium or long-term investment option. Genomic revolution has good growth prospects, which may enable these biotechnology stocks to generate supernormal growth. Moreover, a few of the biotechnology stocks that IDNA holds have started generating positive returns. Besides, the pharmaceutical stocks listed in other equity markets have always maintained a good return.

The overall price growth since the inception of this fund is quite impressive, considering the huge impact of Covid-19 pandemic in the US equity market. Although the portfolio of investments is expected to generate positive return in the medium term, iShares Genomics Immunology and Healthcare ETF is a better prospect for long-term growth-seeking investors. However, it is advisable that such long-term growth seekers hedge themselves with put options, in order to protect their investments from likely downward movements, which may happen from time to time.

See the rest here:
IDNA: A Long Term Prospect, Slowly Overcoming The Bearish Rally - Seeking Alpha

Cell Biology

Frontiers in Cell and Developmental Biology

Scope

Frontiers in Cell and Developmental Biology publishes rigorously peer-reviewed research focusing on the fundamental processes of life.

Indexed in Web of Science (SCIE), Scopus, PubMed and more.

Our latest journal impact metrics reflect the power of research that is open for all. Thanks to our authors, reviewers, and editors for accelerating scientific discovery and developing new solutions.

Continue reading here:
Frontiers in Cell and Developmental Biology

Cell Biology

Cloud Computing in Cell Biology Market Overview with Demographic Data and Industry Growth Trends 2022-2028 Queen Anne and Mangolia News – Queen Anne…

Global Cloud Computing in Cell Biology Market 2022 includes Precise Company profiling of leading players of the Cloud Computing in Cell Biology request. All of the parts studied in the report are anatomized grounded on different factors similar as request share, profit, and CAGR. To more understand the request, its veritably important to consider the opinions of request experts. Cloud Computing in Cell Biology Market report contains expert opinions. Its also divided into sections by type and sections by operation. All types describe the product for the cast period 2022-2028.

The researcher has also completely anatomized different regions similar as North America, Europe, and the Asia Pacific on the base of product, profit, and deals in the Cloud Computing in Cell Biology request. The experimenters used advanced primary and secondary exploration methodologies and tools for preparing this report on the Cloud Computing in Cell Biology request.

Get a Sample PDF of Cloud Computing in Cell Biology Market Report @

https://trouve360reports.com/global-cloud-computing-in-cell-biology-market-58479/?ff_landing=3&form=request-sample

Cloud Computing in Cell Biology Market Size and Growth 2022-2028:

Cloud computing provides fundamental support to address the challenges with shared computing resources including computing, storage, networking and analytical software. Progress in biomedical research is increasingly driven by insight gained through the analysis and interpretation of large and complex data sets. Recently, cloud computing has emerged as a powerful, flexible, and scalable approach to disparate computational and dataintensive problems. researcher predicts global cloud computing in cell biology market will grow from USD 1,798 million in 2021 to USD 5,830 million by 2028, achieving a CAGR of 18.3 percent, according to the latest edition of the Global Cloud Computing in Cell Biology Market Report.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global Cloud Computing in Cell Biology market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, and growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the Cloud Computing in Cell Biology industry.

Top manufacturers of Cloud Computing in Cell Biology Market in 2022:

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the application, and region. The global market for Cloud Computing in Cell Biology can be segmented by application: alloy products, batteries, chemicals, others. Cloud Computing in Cell Biology market is further segmented by region: Asia-Pacific, Europe, North America, Middle East and Africa (MEA), South America.

Any special requirements about this report, please let us know and we can provide custom report.

Cloud Computing in Cell Biology Market Segmentation:

By deployment mode:

Key questions answered in this report-

Table of Content:

PART 1. INTRODUCTION Report description Objectives of the study Market segment Years considered for the report Currency Key target audiencePART 2. METHODOLOGYPART 3. EXECUTIVE SUMMARYPART 4. MARKET OVERVIEW Introduction Drivers Restraints Impact of COVID-19 pandemicPART 5. MARKET BREAKDOWN BY DEPLOYMENT MODE Public cloud Private cloud HybridPART 6. MARKET BREAKDOWN BY APPLICATION Discovery and preclinical research Clinical trials Pharmaceuticals manufacturing OthersPART 7. MARKET BREAKDOWN BY END USER Biotechnology and pharmaceutical companies Clinical laboratories Contract research organization (CRO)PART 8. MARKET BREAKDOWN BY REGION Asia Pacific Europe North America Rest of the World (RoW)PART 9. KEY COMPANIES Accenture plc Alphabet Inc. Amazon Web Services, Inc. Cisco Systems, Inc. Dell Technologies Inc. Huawei Technologies Co., Ltd. International Business Machines Corporation (IBM) Microsoft Corporation Oracle Corporation Salesforce.com Inc. SAP SE

Get Cloud Computing in Cell Biology Market Report @ 2600 USD for a single-user license copy of 72 Pages.

Enquire For Corporate Licence Copy of Cloud Computing in Cell Biology Market @

https://trouve360reports.com/global-cloud-computing-in-cell-biology-market-58479/?ff_landing=6&form=corporate-license

About Trouve 360 Reports:

The growth of your organization depends largely on how much of a grip you have on your market. An elemental part of it is market research. With end-to-end industry reports that cover a plethora of factors, your search ends here at Trouve360reports.

Contact Us

Email us: info@trouve360reports.com

Call Us: +1 (415) 655-1709

Website: https://trouve360reports.com/

Our Social Sites:

https://www.facebook.com/trouve360reports

https://trouve360reports.medium.com/

https://www.linkedin.com/company/trouve360-reports/

Go here to see the original:
Cloud Computing in Cell Biology Market Overview with Demographic Data and Industry Growth Trends 2022-2028 Queen Anne and Mangolia News - Queen Anne...

Cell Biology

Advance in Understanding Cell Division Could Lead to New Cancer Treatments – Weill Cornell Medicine Newsroom

A protein called CDC7, long thought to play an essential role early in the cell division process, is in fact replaceable by another protein called CDK1, according to a study by investigators at Weill Cornell Medicine and the Dana-Farber Cancer Institute. The finding represents a fundamental advance in cell biology and may lead to new cancer therapies, since cancers frequently alter the molecular machinery of cell division to sustain their rapid growth.

The study, published online May 4 in Nature, determined the effects of removing CDC7 in a variety of mammalian cell types, a process that has been difficult to achieve. The results suggest that simultaneously targeting CDC7 and CDK1 could be an effective cancer treatment strategy.

This study provides new insight into one of the most important steps in cell division and suggests a new set of targets for future cancer therapies, said Dr. Tobias Meyer, the Joseph Hinsey Professor in Cell and Developmental Biology and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.

The other co-senior author of the study is Dr. Peter Sicinski, professor of genetics at Harvard Medical School and a researcher at Dana-Farber Cancer Institute, and the first authors are Dr. Jan Suski, a postdoctoral fellow in the Sicinski Lab at Dana-Farber, and Nalin Ratnayeke, a senior graduate student in the Meyer Lab at Weill Cornell Medicine.

The process of cell division, also called the cell cycle, is of central importance in biology. As scientists have learned in recent decades, this process is initiated and controlled by a large set of molecules including the signaling proteins CDK1, CDK4, CDK6 and CDC7. Much is already known about how these proteins orchestrate the start of cell division, and cancer drugs that block cell division by blocking both CDK4 and CDK6 are already in use. But the cell cycle roles of CDK1 and CDC7 have been somewhat murky.

Based on prior experiments primarily in yeast cells, CDC7 was thought to be broadly essential for a key initial step in cell divisionmoving the cell from the preparatory phase of the cell cycle, called G1, into the S phase wherein the cell duplicates its DNA and becomes committed to dividing.

In the new study, the researchers used a variety of new and established protein-removal methods to make a surprising discovery: Selectively deleting the mouse version of CDC7 in different cell types may slow or stop cell division, but only for a day or two before cell division resumes. The researchers found that cells in mice, and presumably in all mammals, can compensate for the loss of CDC7 with increased activity from CDK1even though the latter is structurally very different from CDC7 and had been thought to have a completely separate role in cell division.

The findings illuminate the complex molecular orchestration of the cell cycle, and suggest that simultaneously blocking both CDC7 and CDK1 could be a powerful new strategy against cancer. The researchers are now continuing to tease apart the roles of the different molecular actors in the cell cycle.

This work highlights the surprising fact that cells can sometime achieve redundancy for a given function with two very different classes of proteinnot just with two closely related proteins as were used to seeing, Dr. Meyer said.

See the article here:
Advance in Understanding Cell Division Could Lead to New Cancer Treatments - Weill Cornell Medicine Newsroom

Cell Biology

Cell division in moss and animals more similar than previously thought – EurekAlert

image:Disturbed cell division in the moss mutant affects plant growth (right) compared to wildtype moss (left). view more

Credit: Elena Kozgunova / University of Freiburg

For a new plant to grow from a seed, cells need to divide numerous times. Daughter cells can each take on different tasks and sometimes vary in size. How plants determine the plane of cell division in this process, known as mitosis, is being researched by Prof. Dr. Ralf Reski and Dr. Elena Kozgunova from the University of Freiburg in a joint effort with Prof. Dr. Gohta Goshima from Nagoya University. Working with Physcomitrella a moss plant, they have now identified how the mitotic apparatus is localized in the plant cell: Using moss cells we were able to observe an unexpected process that is important for the position of the cell division site in plants. The process could be far more similar to animal cell division than previously thought, Reski from the cluster of excellence CIBSS comments on the results of the study, which has appeared in the journal Nature Communications.

When cells divide, microtubules a dynamic network of protein filaments form a mitotic spindle that draws the chromosomes apart and arranges them into two daughter cells. Here, plants and animals differ: once the spindle is formed, it remains in the same place in plant cells. In animal cells, the spindle moves during cell division. The cells divide where it comes to rest. The unusual thing about moss cells is that in the process of mitosis they do not form a belt of microtubules and actin filaments, both elements of the cytoskeleton. Until now it was thought that this preprophase band (PPB) determines where the spindles form and where they are localized in plants. But why is the mitotic spindle static in moss cells like in other plants even though there is no preprophase band? wondered Kozgunova, lead author of the study and holder of a Humboldt-Bayer research fellowship in Reskis laboratory.

Mobile spindles previously unknown in plants

To solve this puzzle, the team delved into the molecular biology box of tricks: they modified spreading earthmoss (Physcomitrella) plants, removing five genes. The researchers knew that they resemble the animal gene of a molecule that is significant in mitosis: the protein TPX2 takes part in mitotic spindle assembly in animals.

Under the microscope the researchers observed mitosis in moss plants without the TPX2 genes. They were startled to find that in these cells the spindles now moved during cell division in leafy shoots known as gametophores. Spindle movement had never been documented before in plant cells, explains Kozgunova. Such cells divided irregularly, and as the plant developed, it led to malformations.

Tug-of-war in the cytoskeleton

The researchers now proceeded to influence the actin skeleton of the cells and showed that actin filaments move the mitotic spindle: Its a kind of tug-of-war between microtubules and actin that positions the mitotic spindle in the cell. It appears to be similar to the processes in animal cells, reports Reski. Likewise, actin filaments are important for spindle transport in animal cells. These findings are helping researchers to identify which signals determine the fate of cells as they develop. They hope that this will improve understanding of plant growth and eventually our ability to influence it.

The recordings of the cell division were produced in the Life Imaging Centre, a central facility of the Cluster of Excellence CIBSS Centre for Integrative Biological Signalling Studies at the University of Freiburg.

Factual overview:

Contact:Prof. Dr. Ralf ReskiPlant BiotechnologyFaculty of BiologyUniversity of FreiburgTel.: +49 761 203-6969e-mail: ralf.reski@biologie.uni-freiburg.dewww.plant-biotech.net

Mathilde Bessert-NettelbeckScience CommunicationCluster of Excellence CIBSSUniversity of FreiburgTel.: +49 761 203 97662e-mail: mathilde.bessert-nettelbeck@cibss.uni-freiburg.de

Nature Communications

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more from the original source:
Cell division in moss and animals more similar than previously thought - EurekAlert

Cell Biology

Embattled Researcher Sabatini Withdraws from Consideration for NYU Position – BioSpace

David Sabatini/Courtesy Whitehead Institute (MIT)

David Sabatini has withdrawn his name from consideration for a faculty post at New York University Langone Health.

In a brief statement sent to BioSpace this morning, Sabatini announced his decision. He said false, distorted, and preposterous allegations about him have intensified across news outlets and social media following reports that he was up for a faculty position.

I understand the enormous pressure this has placed on NYU Langone Health and do not want to distract from its important mission. I have therefore decided to withdraw my name from consideration for a faculty position there, Sabatini said in his statement. I deeply respect NYU Langone Healths mission and appreciate the support from individuals who took the time to learn the facts. I remain steadfast in believing that the truth will ultimately emerge and that I will eventually be vindicated and able to return to my research.

Last week, reports surfaced that Sabatini, who was ousted last year by the Whitehead Institute over allegations of sexual harassment, was up for the faculty position at the New York University (NYU) Grossman School of Medicine. The hiring of Sabatini reportedly had the support of Robert Grossman, the medical school dean, as well as Executive Vice President and Vice Dean for Science Dafna Bar-Sagi, Science reported at the time.

When reports of his possible hiring surfaced, concerns over his appointment were raised by current faculty and staff, according to the reports.

A noted cell biology researcher, Sabatini has filed a counter lawsuit against Whitehead alleging he is a victim of false claims. As BioSpace has previously reported, Sabatini claimed in his lawsuit that a sexual relationship between him and his accuser was consensual. Sabatini, who maintained an HHMI-supported lab at the Whitehead Institute, said he ended the relationship in 2019 but that the accuser, a co-worker, did not want things to end. Sabatini claims that he stressed, on multiple occasions that he did not want a long-term relationship. Once he ended the relationship though, she sought revenge, he claimed.

In addition to holding a post at the Whitehead Institute, Sabatini was also a professor at the Massachusetts Institute of Technology, a position he resigned earlier this year ahead of what was likely to be a dismissal following an investigation into his situation. It was likely that he would have been terminated by MIT for violating the schools policy on consensual sexual relationships.

Two years ago, Sabatini, along with Michael Hall from Biozentrum, Universitt Basel in Switzerland, won the Sjberg Prize for their research into cell metabolism and cell growth. The prize was awarded based on discoveries made by researchers that showed proteins that regulate cell growth.Sabatinis discovery was in mammals, which showed the protein, dubbed mTOR, senses nutrients and controls how they are used in vital processes in human cells. In some types of cancer, mTOR has been shown to be overactive and stimulate the growth of cancer cells.

More here:
Embattled Researcher Sabatini Withdraws from Consideration for NYU Position - BioSpace

Cell Biology

3D Cell Culture Market to Reach USD 1846 million in 2024 Size, Share, Growth, Emerging Trends, Top 10 Players and Industry Outlook – Digital Journal

Key players in 3D Cell Culture Market are Thermo Fisher Scientific (US), Corning Incorporated (US), Merck KGaA (Germany), Lonza AG (Switzerland), REPROCELL Incorporated (Japan), TissUse (Germany), InSphero (Switzerland), Synthecon (US), 3D Biotek (US), CN Bio (UK), Hamilton Company (US), MIMETAS (Netherlands), Emulate (US).

3D Cell Culture Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size.

The global 3D cell culture market size is projected to reach USD 1,846 million in 2024 from USD 892 million in 2019, at a CAGR of 15.7%. The growth of this market is driven mainly by the increasing focus on developing alternatives to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, the lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the forecast period.

The study involved four major activities in estimating the current size of the global 3D cell culture market. Exhaustive secondary research was done to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191072847

The scaffold-based 3D cell cultures segment accounted for the largest share of the 3D cell culture market in 2018

Based on product, the market is segmented into scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures. Scaffold-based 3D cell cultures accounted for the largest share of the market in 2018. The advantages of scaffolds in 3D cell culture, such as structural rigidity and the availability of attachment points, have greatly driven the preference for scaffold-based 3D cell cultures and ensured the large share of this segment.

The pharmaceutical & biotechnology companies segment accounted for the largest share of the end-user market in 2018

Based on end user, the market is segmented into pharmaceutical & biotechnology companies, research institutes, the cosmetics industry, and other end users. Pharmaceutical & biotechnology companies accounted for the largest share of the market in 2018. The presence of a large number of pharmaceutical & biotechnology companies, an increase in R&D spending in these companies, and the growing preference for alternative testing models over animal techniques are the key market drivers in this end-user segment.

Market Size Estimation:Both top-down and bottom-up approaches were used to estimate and validate the total size of the global 3D cell culture market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

North America commanded the largest share of the market due to the increasing incidence of cancer and the presence of a well-established pharmaceutical & biotechnology industry. However, the market in Europe is expected to grow at the highest CAGR during the forecast period. The growth of the market in Europe is attributed to the growth of its pharmaceutical and biotechnology industry, recent commercialization ofmicrofluidics-based products, the increasing presence of major market players, and a large number of research activities conducted in the region.

Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=191072847

Thermo Fisher Scientific (US), Corning Incorporated (US), Merck KGaA (Germany), Lonza AG (Switzerland), REPROCELL Incorporated (Japan), TissUse (Germany), InSphero (Switzerland), Synthecon (US), 3D Biotek (US), CN Bio (UK), Hamilton Company (US), MIMETAS (Netherlands), Emulate (US), Hrel Corporation (US), QGel SA (Switzerland), SynVivo (US), Advanced BioMatrix (US), Greiner Bio-One International (Austria), and PromoCell (Germany).

Media ContactCompany Name: MarketsandMarketsContact Person: Mr. Aashish MehraEmail: Send EmailPhone: 18886006441Address:630 Dundee Road Suite 430City: NorthbrookState: IL 60062Country: United StatesWebsite: https://www.marketsandmarkets.com/Market-Reports/3d-cell-culture-market-191072847.html

Originally posted here:
3D Cell Culture Market to Reach USD 1846 million in 2024 Size, Share, Growth, Emerging Trends, Top 10 Players and Industry Outlook - Digital Journal

Cell Biology

CytoSMART Technologies launches the Omni FLan advanced fluorescence live-cell imaging analysis system – Microbioz India

Eindhoven, The Netherlands Life Science Newswire CytoSMART Technologies, an Axion Bio company, today announced the launch of the CytoSMART Omni FL, a next-generation live-cell imaging analysis system incorporating red and green fluorescence channels into its signature CytoSMART Omni product line for the first time. The advance reflects the companys ongoing commitment to provide high-quality, accessible live-cell imaging to every cell biology lab and offers an innovative platform for researchers in stem cell biology, immuno-oncology, virology, toxicology, neurology, and other fields.

Joffry Maltha, CEO at CytoSMART Technologies stated, We are very excited to launch a fluorescence version of the popular brightfield live-cell imager CytoSMART Omni. The new CytoSMART Omni FL brings research to another level and allows scientists to gain greater insight into their experiments while reducing the amount of time spent on manual labor. This advancement represents the next big step in our continued product line innovation strategy designed to accelerate scientific discovery and drug development.

Live-cell fluorescence microscopy is a powerful tool with broad applications in biological research. Using fluorescent tags, dyes, and other methods to label and examine molecules of interest, imaging provides a critical window into the physiology and function of cells over time and enables the creation of high-quality time-lapse videos to track complex cellular processes. Featuring an innovative design that operates efficiently in a cell culture incubator, universal compatibility with any transparent culture vessel, and AI-driven analysis with user-friendly data storage solutions, the low-maintenance CytoSMART Omni FL overcomes the limitations of other imaging platforms and allows for plug-and-play experimentation right out of the box. Applications of live-cell fluorescence imaging include evaluating cell health and viability, assessing wound healing and colony formation, studying transfection efficiency, and investigating complex culture models such as co-cultures and 3D organoids.

According to Axion President and CEO Tom OBrien, CytoSMART has reimagined the microscope, engineering powerful imaging systems that fit comfortably in a standard incubator. While other imaging systems may miss small changes or rare cells or interest, the CytoSMART Omni continuously captures the whole culture surface for a more complete picture. The launch of the Omni FL is another step forward in our mission to provide customers with high-quality instruments and powerful software that rapidly advance live-cell research, as well as cell and gene therapy development.

For more information on CytoSMART Omni FL, visit the official CytoSMART website.

See the article here:
CytoSMART Technologies launches the Omni FLan advanced fluorescence live-cell imaging analysis system - Microbioz India